The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Source: https://www.cnbc.com/2024/04/30/ftc-cha ... empic.html
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
